Following the logic of value-based purchasing, drugs with promise of extending life and treating rare diseases should have a higher purchasing value than those with unclear clinical efficacy results and economic benefits. Sounds reasonable. However, what the healthcare system is lacking is a straightforward method of assessing which drugs are both efficacious and cost-conscious.
To address this need for standardization of the clinical decision making process, The National Pharmaceutical Council is developing “Guiding Practices for Patient-Centered Value Assessment Frameworks”. Leading the pack is Steven Pearson’s Institute for Clinical and Economic Review, known as ICER.
To read more about valuing breakthrough formulas, click here.
Editorial Associate
Lily Stauffer serves as an Editorial Associate for DTC Perspectives. She is currently a senior at Saint Joseph's University, studying Pharmaceutical Marketing and Spanish.
No comments yet.